2nd Annual GPCR Congress, Le Montreux Palace, Switzerland

Oxford Global Conferences is proud to present the GPCR Congress 2010, which is to be held on the 9th &10th June at Le Montreux Palace Hotel in Montreux Switzerland. The congress is the single most focused event in Europe dedicated to key technological and scientific trends in GPCR’s in the pharmaceutical and biotech industry, as well as academic institutions.  It will also be co-located with our 11th Annual Drug Discovery Summit.

G-protein coupled receptors have proven to be a highly amenable target class to successful therapeutic intervention via small-molecule drugs. GPCRs represent 25% of the total pharmaceutically-addressed drug targets today and therefore are the most-druggable target family. This conference therefore explores effective strategies, technologies and applications of GPCR in accelerating drug targeting, discovery and early development. Over two days, the 2 events will attract over 150 senior-level decision makers working in drug targeting, design, discovery and development from the UK, Europe and US.  This prestigious event provides a forum for practitioners and researchers to learn more about key solutions being provided to their industry, network with their peers and address key industry concerns through a series of cutting edge conference presentations in a professional yet relaxed environment, during a 2 day conference programme.

Day 1

GPCR MODULATION
Closer studies into various aspects of GPCR’s including allosteric modulations from both a chemistry and biology aspect, dimerisation and oligomerisation

GPCR SIGNALLING & DISCOVERY GPCR PROGRAMMES
Latest approaches to other important aspects of GPCR’s -  including the role of signaling and trafficking, functional selectivity, polypharmacology and Drug Discovery Programmes

Day 2

GPCR SCREENING
Examining the implementation of GPCR screening methods, HTS, HCS as well as exploring the roles of cell and label free screening, assay technology as well as determining cost effective assay formats.

STRUCTURE & IN SILICO
Focus upon the optimization of all areas of GPCR medicinal chemistry including structure, mechanism, SAR, protein and ligand structure based drug design and molecular and in silico modelling.

 WHO YOU WILL MEET

Delegates are pre-qualified dependent on budget, responsibility and seniority.  Delegates are senior-level decision makers, from major pharmaceutical, biotech companies and research institutions based in Europe and typically include VPs, Directors, Managers and Heads of:
 
Drug Target    Biomarkers        Bioinformatics        Proteomic Chemistry    Drug Design
Screening     Molecular Pharmacology    Molecular Profiling    Medicinal Chemistry    Lead Discovery
Imaging        Protein Engineering    Clinical Diagnostics    Structural Biology        Optimisation & Validation        
SAR        Molecular Biology        Fragment Based        Assay Development    Label Free Technologies
Oligomerisation    Genomics        7tm            Polypharmacology    Allosterism

THE NEW EVENT FORMAT: NETWORKING AND BUSINESS MEETING OPPORTUNITIES

Meet face-to-face with leading solution providers and senior-level industry peers through a series of formal and informal networking opportunities.  Using our online appointment system, you are able to view the full profiles of all solution provides before the event.  In addition you have the chance to pre-arrange one-to-one meetings with them, giving you the opportunity to discuss technologies, services and solutions that address your key business needs.  Categories of solution providers include:

GPCR’s            Assays            Virtual GPCR Testing        Screening Technologies        
Molecular profiling     Biomarkers        Sampling Technologies        High Throughput Applications / Platforms
Medicinal Chemistry    Expression Profiling    Multimarker Diagnostics        Data Management Methods
 

Include:

•    Jonathan Mason, Head of Computational Chemistry, Heptares Therapeutics, UK & Chief Scientist (Predictive Technologies & Drug Design), Medicinal Chemistry, Lundbeck Research, DK
•    Graeme Milligan, Professor of Molecular Pharmacology; Joint Research Director, Faculty of Biomedical and Life Sciences, University of Glasgow
•    Chris van Koppen, Director Molecular Pharmacology, Schering Plough
•    Kevin Pfleger, Research Associate Professor, Head of the Laboratory for Molecular Endocrinology - GPCRs, Western Australian Institute for Medical Research and Centre for Medical Research, University of Western Australia
•    Ross Bathgate, Laboratory Head, Neuropeptide Receptor Laboratory, Howard Florey Institute
•    Ulrich Wendt, Director Structural Biology, Sanofi-Aventis
•    Craig Lindsley, Associate Professor of Pharmacology and Chemistry, Director of Medicinal Chemistry, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center
•    Robert Lane, Post Doctoral Fellow, Faculty of Science, Leiden/Amsterdam Center for Drug Research, Medicinal Chemistry, University of Leiden
•    Steve Garland, Group Leader Lead Generation, GSK
•    Keith Wreggett, Target Biology, Bioscience, AstraZeneca
•    Danilo Guerini, Department of BioChemistry, Novartis
•    Mike Hanson, Associate Director Structural Biology, Receptos
•    Rafael Franco, Professor, Department of Biochemistry and Molecular Biology, University of Barcelona
•    David Gloriam, Department of Medicinal Chemistry, Copenhagen University
•    Jean Mazella, Institut de Pharmacologie Moléculaire et Cellulaire, CNRS
•    Paola Casarosa, Lab Head, Post Development R&D Bronchodilators, Boehringer-Ingelheim Pharma
•    Florian Müllershausen, Laboratory Head Developmental & Molecular Pathways, Novartis
 

Academic £450, Industry £650, Vendor £1250.

Limited time discounts may apply, for more information e-mail at d.morris@oxfordglobal.co.uk or call us at +44 (0)1865 304925